drugset

drugset / Trial / NCT04731727

Treating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL)

NCT04731727 ↗

Phase 0 Not yet recruiting 600 enrolled Kent Wellish MD

NaSingle-groupOpen-labelTreatment

Summary

Study is testing the efficacy of treating corneal thinning conditions with Vitamin B2 (Riboflavin) and the application on UV Light.

Timeline

Start: 2021-06-30
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Riboflavin	Other / unclassified	—	—

Indications